Objective. This meta-analysis evaluated the effects and potential harms of Salvia miltiorrhiza or its extracts Salvianolate and Tanshinone for the treatment of population with a chronic kidney disease (CKD). Methods. We searched for the randomized clinical trials (RCTs) through databases including the Cochrane Library, PubMed, Embase, Web of Science, Current Controlled Trials, China National Knowledge Infrastructure (CNKI), Wanfang Data Knowledge Service Platform (Wanfang Data), China Biology Medicine Disc (SinoMed), and Chinese Clinical Trial Registry (ChiCTR). Meta-analysis was performed with STATA 16 software after data extraction. The risk of bias was assessed with the Cochrane risk-of-bias tool (RoB 2.0), and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework was employed to evaluate the quality of evidence. Result. A total of 32 studies were included involving 2264 participants. Compared to the control group, the treatment group significantly decreased serum creatinine (SCr) (SMD −0.60, 95% CI −0.79 to −0.41, P < 0.0001 ), blood urea nitrogen (BUN) (SMD −0.66, 95% CI −0.81 to −0.50, P < 0.0001 ), Cystatin C (CysC) (SMD −5.16, 95% CI −14.84 to 4.53, P = 0.297 ), 24 hour urine protein (24 h UPE) (SMD −0.70, 95% CI −1.21 to −0.19, P = 0.008 ), time to initiation of dialysis (Log RR 0.43, 95% CI 0.23 to 0.81, P = 0.0089 ), serum total cholesterol (TC) (SMD −0.53, 95% CI −0.88 to −0.17, P = 0.0042 , P = 0.0035 ), plasma fibrinogen (FIB) (SMD −0.79, 95% CI −1.12 to −0.46, P < 0.0001 ), C-reactive protein (CRP) (SMD −0.56, 95% CI −0.93 to −0.19, P = 0.0029 ); increased creatinine clearance (Ccr) (SMD 0.92, 95% CI 0.43 to 1.41, P = 0.0002 ), glomerular filtration rate (GFR) (SMD 0.56, 95% CI 0.30 to 0.83, P < 0.001 ), effective rate (Log RR 0.30, 95% CI 0.23 to 0.37, P < 0.0001 ), and hemoglobin (Hb) (SMD 0.42, 95% CI 0.13 to 0.71, P = 0.0042 ). Moreover, the incidences of adverse effects were similar between the two groups. Conclusions. Salvia miltiorrhiza or its extracts Salvianolate and Tanshinone, as a complementary therapy to conventional medicine, presents potential impacts to improve kidney functions and delay the progression of CKD without obvious adverse effects. However, the certainty of the evidence and the risk of bias are suboptimal and further clinical studies are still required to determine the underlying effects.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.